<DOC>
	<DOCNO>NCT00130442</DOCNO>
	<brief_summary>The aim study compare safety effectiveness new drug call PI-88 , use combination approve chemotherapy drug call dacarbazine , treatment metastatic melanoma . PI-88 block new blood vessel growth tumour ( starves nutrient ) dacarbazine stops cancer cell grow . The result study analysed see worthwhile two drug test future study involve large number melanoma patient .</brief_summary>
	<brief_title>Trial PI-88 With Dacarbazine Patients With Metastatic Melanoma</brief_title>
	<detailed_description>Metastatic melanoma difficult-to-treat cancer available treatment option limit minimally effective . Dacarbazine currently one standard chemotherapy drug use treatment metastatic melanoma . However , associate low response rate ( 10-20 % ) median survival le 12 month ( 6-11 month study ) . PI-88 antiangiogenic antimetastatic drug already show evidence efficacy use alone intermittent dosage regimen ( 4 consecutive day per week ) treatment patient advance melanoma . The FDA designate PI-88 Orphan Drug indication , well Stage III high-risk stage II disease . The aim randomise pilot phase II trial determine whether PI-88 combination standard regimen dacarbazine ( 1000 mg/m2 every 3 week ) consider investigation larger-scale trial .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically prove metastatic melanoma Surgery feasible inappropriate Measurable disease . Metastatic lesion must measurable magnetic resonance imaging ( MRI ) compute tomography ( CT ) define Response Evaluation Criteria Solid Tumors ( RECIST ) , cutaneous lesion physical examination . Have voluntarily give write informed consent participate study Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy least 3 month Neutrophil count &gt; 1.5 x 10^9/L ( 1,500/mm3 ) Platelet count &gt; 100 x 10^9/L ( 100,000/mm3 ) Acceptable liver function test ( see Exclusion Criteria maximum allowable elevation ALT , AST , ALP LDH ) PT &lt; 1.5 x upper limit normal ( ULN ) APTT &lt; 1.5 x ULN Creatinine clearance &gt; 40 mL/min , calculate use CockcroftGault formula ( 40 mL/min , GFR &gt; 40 mL/min determine 24hour urine collection ) Current history central nervous system involvement , brain meningeal metastases Ocular melanoma Clinically significant nonmalignant disease Prior coexistent malignancy ( stage I internal malignancy treat diseasefree &gt; 5 year , nonmelanomatous skin cancer situ cancer cervix ) Prior chemotherapy Prior treatment vaccine and/or biological response modifier within previous 4 week Prior treatment radiotherapy within previous 4 week ( local palliative radiotherapy permit ) Radiotherapy &gt; 30 % marrowbearing bone within previous 3 month Major surgery within past 4 week Concomitant use aspirin ( &gt; 150 mg/day ) , nonsteroidal antiinflammatory drug ( except specific COX2 inhibitor ) , heparin , low molecular weight heparin , warfarin ( &gt; 1 mg/day ) antiplatelet drug ( abciximab , clopidogrel , dipyridamole , ticlopidine tirofiban ) . Lowdose aspirin ( ≤ 150 mg/day ) lowdose warfarin ( ≤ 1 mg/day ) permit concomitant medication . Heparin low molecular weight heparin within previous 2 week History acute chronic gastrointestinal bleeding within last 2 year , inflammatory bowel disease abnormal bleeding tendency Patients risk bleed due open wound plan surgery Bilirubin &gt; 1.5 x ULN AST ALT &gt; 3 x ULN unless patient hepatic metastasis LDH &gt; 2 x ULN Alkaline phosphatase &gt; 5 x ULN , unless patient bone metastases Myocardial infarction , stroke congestive heart failure within past 3 month Women pregnant breast feed Women childbearing potential pregnancy exclude use adequate method contraception History allergy and/or hypersensitivity anticoagulants/thrombolytic agent , especially heparin History immunemediated thrombocytopenia , thrombotic thrombocytopenic purpura platelet disease , laboratory evidence antiheparin antibody Uncontrolled serious infection within past 4 week Patients unable compliant follow instruction give clinic staff</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>phase II</keyword>
	<keyword>metastatic melanoma</keyword>
	<keyword>dacarbazine</keyword>
	<keyword>combination</keyword>
	<keyword>PI-88</keyword>
</DOC>